Jump to any asset
849 assets, updated daily
As of September 27, 2026, Amgen Inc. (AMGN) trades at $414.61. CleaRank Financial AI rates it Hold with a fair value of $395.00, 4.7% below the current price. Wall Street's consensus target is $395.00 across 33 analysts. RSI at 40 is in neutral territory, and the price is above its 50-day average of $404.70.
Amgen Inc. (AMGN)
Amgen Inc. NASDAQ
$414.61
8.570 (2.11%)
At close: Sep 25, 4:00 PM EDT
AI Analyst Consensus
57 / 100
Amgen Inc. (AMGN) is currently trading at $414.61, above its 50-day and 200-day moving averages ($404.70 and $362.12), suggesting some positive technical momentum. However, the stock's valuation appears stretched relative to its sector, with a price-to-sales ratio of 5.88 compared to the sector median of 3.7. Analysts maintain a 'Hold' consensus with a median price target of $395, implying a slight downside from current levels. Financially, Amgen demonstrates strong profitability with a net profit margin of 22.95% and a strong return on equity of 91.47%. The company also boasts a significant cash position, though its debt-to-equity ratio is high at 4.90, aligning with the sector average. Despite these strengths, the current analyst sentiment and valuation suggest a cautious outlook for near-term price appreciation.
AMGN Price Analysis
Market Metrics
Open
$408.25
Day Range
$404.19 to $415.20
Prev Close
$406.04
Volume
2.21M
52-Week Range
$269.77 to $447.03
Market Cap
$224.15B
Peer Benchmarking
Valuation vs Sector (Healthcare)
Performance vs XLV
Sector Position Analysis
Valuation is broadly in line with sector peers (-19% difference), suggesting fair market pricing relative to industry standards.
AMGN Financial Performance
Revenue vs. Earnings
Annual
Quarterly
Earnings Reality Check
Analysis: In the last 5 quarters, AMGN beat estimates 5 times. The stock rose 4 times the next day. Price tends to react positively to beats.
AMGN Analysis
Company's Health
4/5
12-Month Analyst Target
-4.73% Downside
Median of 33 analysts (12-month)
$395.00
AI Technical Analysis
Amgen Inc. (AMGN) is currently trading at $414.61, above its 50-day SMA of $404.70 and its 200-day SMA of $362.12, indicating a generally positive trend. The Relative Strength Index (RSI) is at 40.35, signaling neutral momentum, neither overbought nor oversold. The MACD is currently negative at -2.42, suggesting some bearish pressure in the short term, though it is trading above its 20-day EMA. Key support levels are near the 50-day SMA around $404.70, while resistance may be found near recent highs. Volume has been below average recently, with 2.21 million shares traded compared to a 3.37 million average, indicating a lack of strong conviction from traders. The current technical setup suggests a consolidation phase rather than a strong directional move.
ProTips
- Given the 'Hold' consensus and median price target below current levels, consider waiting for a more favorable entry point or clearer bullish signals before increasing exposure to Amgen Inc. (AMGN).
- Amgen Inc. (AMGN) is trading above its 50-day and 200-day moving averages ($404.70 and $362.12), but with neutral RSI and slightly negative MACD, the technical picture suggests a period of consolidation rather than a strong breakout.
- With insider selling dominating recent transactions, it may be prudent to monitor future insider activity closely for any shifts in sentiment that could impact the stock's trajectory.
Key Catalysts
Bearish
Moderate Insider Selling Signal
Insiders have sold $30.4 million worth of Amgen Inc. (AMGN) stock, with no reported purchases, indicating a potential lack of confidence in near-term price appreciation.
Source: Insider TransactionsBearish
Analyst Downgrades and Price Target Reductions
Recent analyst actions include downgrades from 'Buy' to 'Hold' by HSBC and BMO Capital, reflecting concerns about valuation and limited upside potential.
Source: Analyst RatingsBullish
Strong Earnings Beat in Q2 2026
Amgen Inc. (AMGN) exceeded EPS estimates by 11.92% for the quarter ending June 2026, leading to a positive stock price reaction and demonstrating operational strength.
Source: Earnings ReportNeutral
Continued Revenue Growth Projections
Wall Street forecasts revenue growth of 6.00% for the current year and 3.00% for the next, indicating steady top-line expansion for Amgen Inc. (AMGN).
Source: Analyst EstimatesMarket Outlook
Amgen Inc. (AMGN) is expected to maintain its position as a leading biotechnology company, with forward revenue growth projected at 6.00% for the current year and 3.00% for the next. The company's strong profitability and consistent earnings beats provide a solid foundation, but the current 'Hold' consensus and median price target below the current price suggest limited near-term upside potential. The stock's current trading above key moving averages offers some technical support. Future performance will likely depend on the successful development and commercialization of its pipeline drugs and continued execution in its existing therapeutic areas. Key upside catalysts could include positive clinical trial results or unexpected M&A activity, while downside risks include increased competition, regulatory hurdles, or a failure to meet aggressive growth expectations. The high debt-to-equity ratio also warrants monitoring in a rising interest rate environment.
Key Statistics
| Market Cap | 224.15B |
|---|---|
| P/E Ratio | 25.77 |
| EPS (TTM) | 16.09 |
| Dividend Yield | 2.40% |
| 52 Week High | 447.03 |
| 52 Week Low | 269.77 |
Amgen Inc. (AMGN) exhibits a price-to-sales ratio of 5.88, which is notably higher than the healthcare sector median of 3.7, suggesting the stock may be trading at a premium. Its earnings per share (EPS) stands at $16.09, with a P/E ratio of 25.77, also appearing elevated compared to the sector average P/E of 31.9, but this needs to be viewed in context of its strong profitability. The company demonstrates exceptional profitability with a net profit margin of 22.95% and a return on equity of 91.47%, significantly outperforming sector averages. However, its debt-to-equity ratio of 4.90 is high, though in line with the sector. While fundamentals are strong, the current valuation and analyst sentiment suggest that the market may be pricing in significant future growth that could be challenging to achieve.
Earnings & Growth Analysis
Amgen Inc. (AMGN) most recently reported earnings for the quarter ending June 2026, with an actual EPS of $6.29, beating the estimated $5.62 by 11.92% and leading to a 4.57% price increase. Prior to this, the company missed estimates for the quarter ending December 2025, reporting an EPS of -0.09 against an estimate of -0.33, a 72.73% surprise, which resulted in a 0.32% price change. The company has shown a mixed but generally positive earnings surprise trend over the last few reported quarters, indicating operational resilience.
Key Risks
Amgen Inc. (AMGN) faces the risk of its valuation being too high, as its price-to-sales ratio exceeds the sector median, and the median analyst price target suggests limited upside. Also, insider activity shows a 'Moderate Sell Signal' with $30.4 million in sales versus no reported purchases, indicating a lack of insider confidence in near-term price appreciation. The company's high debt-to-equity ratio of 4.90 also presents a financial risk, especially if interest rates rise or earnings falter.
Technical Indicators
| RSI (14) | 40.35 |
|---|---|
| MACD | -2.42 |
| SMA 50 | 404.70 |
| SMA 200 | 362.12 |
RSI
Neutral
SMA Cross
Bullish
Price vs SMA
Bullish
MACD
Bearish
Golden Cross in effect with the 50-day SMA ($404.70) above the 200-day SMA ($362.12), price action is firmly bullish above key moving averages.
Market Correlations
How this stock moves relative to other assets
Based on 1 year of daily price data. Correlations may vary over different time periods.
S&P 500 (SPY)
+0.28
Weak correlation
Nasdaq 100 (QQQ)
+0.18
Weak correlation
Bitcoin (BTC)
+0.12
Weak correlation
Gold (XAU)
+0.14
Weak correlation
Check Custom Correlation
How does any other asset move with AMGN? One year of daily closes, Pearson correlation.
Try
AMGN Trade Plans
Specific entry, exit, and risk management levels
Select Your Trade Bias
Risk Tolerance
Conservative
2%
Aggressive
Portfolio Value
$
Position Size: Enter portfolio size →
Entry Strategies pick an entry style
Conservative
$410.46
Slight discount to current
Wait for small dip
Aggressive
$414.61
At current price
Enter now if confident
Risk Management
STOP LOSS
$393.68
MAX LOSS
-4.1%
Volatility-Adjusted Stop Loss
Calculated based on RSI (40.4) and current market volatility
Profit Targets (Based on Conservative Entry)
TARGET 1
$422.78
+3% (Conservative)
+2.0% (Aggressive)
TARGET 2
$430.99
+5% (Conservative)
+3.9% (Aggressive)
TARGET 3
$443.30
+8% (Conservative)
+6.9% (Aggressive)
Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3
Calculate Your Trade
Disclaimer
This AI-generated trade plan for AMGN is for educational and informational purposes only and does not constitute financial advice. The analysis is based on historical data patterns and technical indicators which may not predict future results. Stock trading involves risk of loss. Verify all data independently and consult a qualified financial advisor. Generated on September 27, 2026.Growth of $10,000
A $10,000 investment in AMGN in September 2016 would be worth about $24,157 today, compared with about $35,782 for the same investment in the S&P 500 benchmark.
Compare with Another Ticker
Monte Carlo Projection (10yr)
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in AMGN today could grow to about $22,054 by 2036 in the base case, with a bull case near $61,369 and a bear case around $7,925. Projections are statistical simulations, not guarantees.
AMGN Stock Price Prediction: 2030
CleaRank's simulation projects a price near $569 for AMGN by 2030 in the base case, from $415 today (1.4x over 4 years). The downside path ends near $298. These are outcomes of a Monte Carlo simulation run on AMGN's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | Downside (10th pct) | Base case | Upside (90th pct) |
|---|---|---|---|
| 2027 | $325 | $449 | $620 |
| 2028 | $307 | $486 | $768 |
| 2029 | $300 | $526 | $921 |
| 2030 | $298 | $569 | $1,087 |
| 2031 | $299 | $616 | $1,270 |
| 2032 | $302 | $666 | $1,472 |
| 2033 | $306 | $721 | $1,698 |
| 2034 | $313 | $781 | $1,950 |
| 2035 | $320 | $845 | $2,231 |
| 2036 | $329 | $914 | $2,544 |
Method: 10,000 simulated price paths using AMGN's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice.
People Also Watch
AMGN Insider Trading Analysis
Bought
None
No open-market buys
Sold
$30.4M
12 Transactions
Insiders
22
Active Traders
Avg Transaction
$2.5M
Large trades
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Feb 26, 2026 | SANTOS ESTEBAN
Officer
|
Sell | 54.8K | $20.8M |
| Feb 21, 2025 | REESE DAVID M.
Chief Technology Officer
|
Sell | 33.9K | $10.2M |
| Feb 7, 2025 | GRAHAM JONATHAN P
General Counsel
|
Sell | 25.0K | $7.3M |
| May 10, 2022 | GRAHAM JONATHAN P
General Counsel
|
Sell | 13.5K | $3.3M |
| Aug 30, 2019 | PATTON CYNTHIA M
Officer
|
Sell | 13.4K | $2.8M |
| Nov 8, 2023 | GRAHAM JONATHAN P
General Counsel
|
Sell | 10.0K | $2.7M |
| Feb 4, 2021 | GRAHAM JONATHAN P
General Counsel
|
Sell | 11.1K | $2.6M |
| Feb 11, 2025 | GORDON MURDO
Officer
|
Sell | 8.8K | $2.6M |
| Feb 19, 2025 | SANTOS ESTEBAN
Officer
|
Sell | 8.7K | $2.6M |
| Aug 10, 2023 | GORDON MURDO
Officer
|
Sell | 9.6K | $2.5M |
Page 1 of 1
Frequently Asked Questions
What is Amgen Inc.'s current stock price and consensus rating?
Amgen Inc. (AMGN) is currently trading at $414.61 per share. The consensus rating among analysts is 'Hold', with a consensus score of 57 out of 100.
What is the median analyst price target for AMGN stock?
The median analyst price target for Amgen Inc. (AMGN) is $395.00, which represents a -4.7% downside from its current trading price.
How does Amgen Inc.'s valuation compare to its sector peers?
Amgen Inc. (AMGN) has a price-to-sales ratio of 5.88, which is higher than the healthcare sector median of 3.7, suggesting it may be trading at a premium relative to its peers.
What is Amgen Inc.'s recent earnings performance?
In the quarter ending June 2026, Amgen Inc. (AMGN) reported an EPS of $6.29, beating estimates by 11.92% and leading to a positive stock price reaction. The company has shown a generally positive earnings surprise trend recently.
Are Amgen Inc. insiders buying or selling stock?
Insiders at Amgen Inc. (AMGN) are net sellers, with $30.4 million in total sales and no reported purchases in recent filings. This is classified as a 'Moderate Sell Signal'.
What are the key technical indicators for AMGN stock?
Amgen Inc. (AMGN) is trading above its 50-day and 200-day moving averages ($404.70 and $362.12), indicating a positive trend. The RSI is neutral at 40.35, and the MACD is slightly negative, suggesting a consolidation phase with limited immediate upside momentum.
What is Amgen Inc.'s long-range stock projection for 2030?
Based on Monte Carlo simulations, Amgen Inc. (AMGN) has a base case projection of $568.90 for 2030, with a downside projection of $297.80 and an upside projection of $1086.77. These are statistical outcomes, not guarantees.
What is Amgen Inc.'s dividend yield?
Amgen Inc. (AMGN) currently offers a dividend yield of approximately 2.40%.